• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2005 Fiscal Year Final Research Report Summary

Combination therapy with immunotherapy and chemotherapy for pancreatic cancer. -Aim at the standardization of clinical trial for immuno-chemotherapy-

Research Project

Project/Area Number 16591324
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionYamaguchi University

Principal Investigator

YAMAMOTO Koutaro  Yamaguchi University, Faculty of Medicine, Researcher, 医学部, 非常勤研究員 (50304481)

Co-Investigator(Kenkyū-buntansha) YOSHINO Shigefumi  Yamaguchi University, Faculty of Medicine, Assistant Professor, 医学部, 講師 (60294633)
UENO Tomio  Yamaguchi University, Hospital, Research Associate, 医学部附属病院, 助手 (70284255)
HAZAMA Shoichi  Yamaguchi University, Hospital, Assistant Professor, 医学部附属病院, 講師 (50253159)
OKA Masaaki  Yamaguchi University, Faculty of Medicine, Professor, 医学部, 教授 (70144946)
Project Period (FY) 2004 – 2005
KeywordsPancreatic cancer / Immunotherapy / Chemotherapy / Peptide vaccination / Gemcitabine
Research Abstract

On this project, we attempted to find clinically effective therapy against pancreatic cancer using the combination with immunotherapy and chemotherapy. We reported two phase I trials of MUC1 peptide vaccination and personalized peptide vaccination within the term of this project. We vaccinated 9 patients with 300,1000,or 3000 mg of the 105 amino acid MUC1 peptide. There were no adverse events, except for mild reddening and swelling at the vaccination site. In 8 patients eligible for clinical evaluation,7 had progressive disease and 1 stable disease with a tendency for increased circulating anti-MUC1 IgG antibody after vaccination. Secondary we applied another phase I study with personalized peptide vaccination to 11 patients with pancreatic cancer. Namely, pre-vaccinated peripheral blood mononuclear cells were screened for the reactivity in vitro to each of 14 or 16 peptide candidates in HLA-A24^+ or -A2^+ patients, and then only the reactive peptides were vaccinated in vivo. This regimen was generally well tolerated without hematological toxicity, although inflammatory reactions at the injection site were observed in 7 patients. Increased cellular and humoral immune responses to at least one of peptides used for vaccination were observed in the post-vaccination PBMCs and sera from 4 of 8 patients and 4 of 10 patients tested, respectively. The 6- and 12-month survival rates for patients who received more than 3 vaccinations (n=10) were 80% and 20%, respectively. On the base of two phase I study, we conducted a phase I trial of combination therapy with personalized peptide immunotherapy and chemotherapy using GEM for pancreatic cancer. We vaccinated 13 patients with 1,2,or 3 mg of the reactive peptides. There were no adverse events, and a dose of 3 mg was recommended. After this project, a phase II study of combination therapy with personalized peptide immunotherapy and chemotherapy using GEM for pancreatic cancer is warranted.

  • Research Products

    (4 results)

All 2005

All Journal Article (4 results)

  • [Journal Article] Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.2005

    • Author(s)
      Yamamoto K, et al.
    • Journal Title

      Oncology Report 13・5

      Pages: 874-883

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer.2005

    • Author(s)
      Yamamoto K, et al.
    • Journal Title

      Anticancer Research 25・5

      Pages: 3575-3579

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Immunological Evaluation of Personalized Peptide Vaccination for Patients with Pancreatic Cancer.2005

    • Author(s)
      Koutaro Yamamoto
    • Journal Title

      Oncology Reports vol.13

      Pages: 874-883

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] MUC1 Peptide Vaccination in Patients with Advanced Pancreas or Biliary Tract Cancer.2005

    • Author(s)
      Koutaro Yamamoto
    • Journal Title

      Anticancer Research Vol.25

      Pages: 3575-3579

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2007-12-13  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi